Literature DB >> 15122792

Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan.

Hidenori Toyoda1, Kazuhiko Hayashi, Yoshiki Murakami, Takashi Honda, Yoshiaki Katano, Isao Nakano, Hidemi Goto, Takashi Kumada, Junki Takamatsu.   

Abstract

The prevalence and clinical implications of occult hepatitis B virus (HBV) infection were investigated in the Japanese patients with hemophilia in whom a high prevalence of infection with transfusion-transmissible viruses has been reported. HBV DNA was detected in the sera of 22 of 43 (51.2%) patients with hemophilia who were negative for HBV surface antigen (HBs), indicating that these patients had occult HBV infection. No factor, including age, type or severity of hemophilia, presence of HBs or HBV core (HBc) antibody, or coinfection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV) was associated with occult HBV infection, except for high anti-HBc titer and/or coinfection with HCV genotype 1 (1a or 1b). In general, occult HBV infection did not appear to have significant clinical implications. However, in patients in whom HBV was detected by PCR specific for the surface (S)-region, higher alanine aminotransferase levels were observed. The genotype of the occult HBV in the present study was exclusively the domestic type indigenous to Japan (genotype C), suggesting a different route of transmission for HBV in comparison to HCV and HIV in this population. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122792     DOI: 10.1002/jmv.20075

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Prevalence of occult HBV infection in haemodialysis patients with chronic HCV.

Authors:  Vedat Goral; Hamza Ozkul; Selahattin Tekes; Dede Sit; Ali Kemal Kadiroglu
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

Review 2.  Managing hepatitis B coinfection in HIV-infected patients.

Authors:  Marion G Peters
Journal:  Curr HIV/AIDS Rep       Date:  2005-08       Impact factor: 5.071

Review 3.  Occult hepatitis B virus infection.

Authors:  Min-Sun Kwak; Yoon Jun Kim
Journal:  World J Hepatol       Date:  2014-12-27

4.  Detection of hepatitis B virus DNA among accepted blood donors in Nanjing, China.

Authors:  Yong Liu; Ping Li; Cuiping Li; Jinyong Zhou; Chao Wu; Yi-Hua Zhou
Journal:  Virol J       Date:  2010-08-19       Impact factor: 4.099

Review 5.  Occult HBV infection.

Authors:  Giovanni Raimondo; Gaia Caccamo; Roberto Filomia; Teresa Pollicino
Journal:  Semin Immunopathol       Date:  2012-07-26       Impact factor: 9.623

6.  Epidemiology of occult hepatitis B infection among thalassemic, hemophilia, and hemodialysis patients.

Authors:  Mohammad Kazemi Arababadi; Behzad Nasiri Ahmadabadi; Hassan Yousefi Daredor; Derek Kennedy
Journal:  Hepat Mon       Date:  2012-05-30       Impact factor: 0.660

7.  Occult hepatitis B among Iranian hepatitis C patients.

Authors:  Ahmad Shavakhi; Babak Norinayer; Fateme Sadat Esteghamat; Mohamad Seghatoleslami; Mahsa Khodadustan; Mohamad Hosein Somi; Mohsen Masoodi; Mohamad Reza Zali
Journal:  J Res Med Sci       Date:  2009-01       Impact factor: 1.852

8.  Post-transfusion occult hepatitis B (OBI): a global challenge for blood recipients and health authorities.

Authors:  Mohammad Kazemi Arababadi; Gholamhossein Hassanshahi; Ali Akbar Pourfathollah; Ebrahim Rezazadeh Zarandi; Derek Kennedy
Journal:  Hepat Mon       Date:  2011-09       Impact factor: 0.660

9.  Prevalence of occult hepatitis B virus infection in hemodialysis patients from egypt with or without hepatitis C virus infection.

Authors:  Mona A Abu El Makarem; Mohammed Abdel Hamid; Ashraf Abdel Aleem; Ahmed Ali; Mohammed Shatat; Douaa Sayed; Ali Deaf; Lamia Hamdy; Effat A Tony
Journal:  Hepat Mon       Date:  2012-04-30       Impact factor: 0.660

10.  Prevalence of hepatitis B and C infections and HCV genotypes among haemophilia patients in ahvaz, southwest iran.

Authors:  Mohammad Ali Assarehzadegan; Mehri Ghafourian Boroujerdnia; Khodamorad Zandian
Journal:  Iran Red Crescent Med J       Date:  2012-08-30       Impact factor: 0.611

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.